320337-22-2

Upstream product

• 97674-02-7 tributyl(1-ethoxyvinyl)stannane 
• 231278-20-9 N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine 
• 98556-31-1 4-chloro-6-iodoquinazoline 
• 202197-26-0 3-chloro-4-(3-fluorobenzyloxy)aniline 
• 619-08-9 2-chloro-4-nitrophenol 
• 456-41-7 1-(Bromomethyl)-3-fluorobenzene 
• 443882-99-3 3-chloro-4-(3-fluorobenzyloxy)nitrobenzene 
• 202197-25-9 {4-[(3-fluorobenzyl)oxy]phenyl}amine 

Downstream Products

• 443883-07-6 N-{4-[(3-fluorobenzyloxy)]-chlorophenyl}-6-[2-({[2-(methanesulphonyl)ethyl]-[trifluoroacetyl]amino}methyl)-1,3-thiazol-4-yl]-(quinazolin-4-yl)-amine 
• 388082-81-3 (4-(3-fluoro-benzyloxy)-3-chlorophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)methyl)-thiazol-4-yl)-quinazolin-4-yl)-amine 
• 443883-09-8 N-(4-(3-fluorobenzyloxy)-3-chlorophenyl)-(6-(2-bromoethanone)-quinazolin-4-yl)-amine 

Relevant academic research and scientific papers

CANCER TREATMENT METHOD

A method of treating cancer is described including administration of a 4-quinazolineamine and at least one other anti-neoplastic agent as well as a pharmaceutical combination including the 4-quinazolineamines.

CANCER TREATMENT METHOD

A method of treating cancer is described including administration of a pyrimidine derivative and a quinazoline derivative as well as a pharmaceutical composition including the same.

Discovery and biological evaluation of potent dual ErbB-2/EGFR tyrosine kinase inhibitors: 6-Thiazolylquinazolines

We have identified a novel class of 6-thiazolylquinazolines as potent and selective inhibitors of both ErbB-2 and EGFR tyrosine kinase activity, with IC50 values in the nanomolar range. These compounds inhibited the growth of both EGFR (HN5) and ErbB-2 (BT474) over-expressing human tumor cell lines in vitro. Using xenograft models of the same cell lines, we found that the compounds given orally inhibited in vivo tumor growth significantly compared with control animals.